INS and hyperlipidemia: It reduces insulin efficiency in insulin-responsive tissues (muscle, fat, and liver), which conversely causes a decompensated increase in insulin and hyperinsulinemia, and then leads to chronic metabolic disorders (hyperglycemia, hypertension, hyperlipidemia, etc.)and inflammation (10–14).